Journal of Affective Disorders
July 1, 2022
T. D. Hull, Matteo Malgaroli, A. Gazzaley et al.
59 citations
At-home ketamine-assisted therapy with remote monitoring produced rapid and significant improvements in depression and anxiety. Among 1247 patients, 62.8% showed at least 50% improvement on the depression scale and 62.9% on the anxiety scale, with remission rates of 32.6% and 31.3%, respectively. Deterioration was rare (0.9% for depression, 0.6% for anxiety). Three patient subpopulations emerged: those who improved steadily (79.3%), those with delayed improvement (9.3%), and a chronic group (11.4%) who were more likely to report dissociation at the fourth session. Side effects at the second session predicted delayed improvement. Only six patients discontinued early due to side effects or adverse events, indicating that screening and monitoring kept risks low.
Journal of Psychoactive Drugs
October 11, 2022
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
11 citations
After decades of limited research, interest in using psychedelics as psychiatric treatments has revived. A bibliometric analysis of 394 clinical studies on 5-MeO-DMT, ayahuasca, DMT, LSD, ibogaine, mescaline, MDMA, and psilocybin published from 1965 to 2021 found that publications resurged after a lull from the 1970s to the 1990s. MDMA was the most frequently studied substance (49%), followed by LSD (19%), psilocybin (18%), and ayahuasca (7%). Comparing studies from 1965-2009 with those from 2010-2021, the recent cohort had a higher proportion of studies on therapeutic applications and a lower proportion on effects in non-research settings. Psilocybin studies increased proportionally, while DMT and mescaline studies decreased. Researchers in the United Kingdom had the most diverse international collaborations.
Figshare
January 1, 2021
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
A dataset was compiled for a bibliometric analysis of journal articles reporting clinical study findings on eight psychedelic substances—5-MeO-DMT, ayahuasca, DMT, ibogaine, LSD, mescaline, MDMA, and psilocybin—published between 1965 and 2018. The dataset accompanies a preprint article that analyzes the academic literature on these compounds.